Go Deep
Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,763 | 1.0 | 0.55 | 0.00 | 397.12 |
| Oct 2026 | 22,792 | 1.0 | 0.54 | 0.00 | 393.08 |
| Oct 2026 | 22,753 | 1.0 | 0.55 | 0.00 | 396.94 |
| Oct 2026 | 22,861 | 1.0 | 0.53 | 0.00 | 385.49 |
| Oct 2026 | 22,670 | 1.0 | 0.53 | 0.00 | 384.95 |
| Oct 2026 | 22,582 | 1.0 | 0.54 | 0.00 | 393.49 |
| Oct 2026 | 22,592 | 1.0 | 0.54 | 0.00 | 391.57 |
| Oct 2026 | 22,612 | 1.0 | 0.54 | 0.00 | 388.89 |
Oramed Pharmaceuticals Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 78,156,000.0 | 38,310,000.0 | 10,009,000.0 | 48,395,000.0 |
| EPS | 1.9 | 0.9 | — | 1.2 |
Oramed Pharmaceuticals Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 2,000,000.0 | 0.0 | 1,340,000.0 | 2,703,000.0 |
| Net Profit | 64,050,000.0 | -19,060,000.0 | 5,525,000.0 | -36,561,000.0 |
| EPS | 1.5 | -0.5 | 0.1 | -0.9 |
Oramed Pharmaceuticals Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 230,864,000.0 | 155,278,000.0 | 220,551,000.0 | 161,642,000.0 |
| Total Liabilities | 31,120,000.0 | 9,931,000.0 | 57,658,000.0 | 10,486,000.0 |
| Total Equity | 199,744,000.0 | 146,265,000.0 | 163,821,000.0 | 151,812,000.0 |
Owes vs Owns
Oramed Pharmaceuticals Inc. owed $0.14 for every $1 it owned in Jun 2026, up from $0.06 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.14× | 0.13× | 0.06× | 0.26× | 0.06× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Oramed Pharmaceuticals Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 54.5%Receivables 2.0%Fixed assets (tangible) 0.6%Long-term investments 40.6%Other assets 2.3%
How it's funded — Dec 2025
Other liabilities 12.9%Shareholders' equity 86.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 125.9 | 141.9 | 162.0 | 155.7 |
| Receivables | 4.6 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.3 | 1.1 | 1.6 | 1.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 93.7 | 10.9 | 54.9 | 2.7 |
| Other assets | 5.3 | 1.3 | 2.0 | 1.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.3 | 0.2 | 51.0 | 0.2 |
| Long-term debt | 0.5 | 0.2 | 0.3 | 0.6 |
| Payables | 0.4 | 0.8 | 0.6 | 2.2 |
| Other liabilities | 29.9 | 8.8 | 5.8 | 7.4 |
| Shareholders' equity | 199.7 | 145.3 | 162.9 | 151.2 |
| Net tangible assets | 199.7 | 146.3 | 163.8 | 151.8 |
Oramed Pharmaceuticals Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -9,145,000.0 | -8,412,000.0 | -10,295,000.0 | -27,918,000.0 |
| Investing Activities | 5,443,000.0 | 105,817,000.0 | -73,038,000.0 | 30,211,000.0 |
| Financing Activities | -4,741,000.0 | -52,036,000.0 | 51,978,000.0 | 10,779,000.0 |